Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Launched by NATIONAL CANCER INSTITUTE LAO · Jun 15, 2015
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on collecting and storing tissue and blood samples from people diagnosed with cancer. The goal is to use these samples to help scientists better understand cancer and to test new treatments. By studying these samples in a lab, researchers hope to create improved models that can lead to better cancer therapies in the future.
To participate, you need to be at least 18 years old and have a confirmed diagnosis of cancer, or be under evaluation for a possible cancer diagnosis. This includes patients with various forms of cancer, whether it's newly diagnosed, recurrent, or currently being treated. If you choose to participate, you'll be asked to provide blood and tissue samples, which will be collected at specific times related to your treatment. It's important to know that your participation will help advance cancer research, and you’ll need to sign a consent form agreeing to the use of your samples for this purpose.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites
- • Patients with a histologically or cytologically confirmed diagnosis of cancer
- • Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
- * Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician:
- • Radiographic imaging (computed tomography \[CT\], magnetic resonance imaging \[MRI\], etc.)
- • Elevated tumor markers
- • Clinical symptoms
- • Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome
- • Complete blood count (CBC) w/differential indicative of a probable hematologic malignancy
- • If the patient will be undergoing surgical resection at a later time and will be accessible to approach for study participation at that time, resected material following cancer diagnosis confirmation is preferred
- • Important: Additional medical, genetic and/or demographic work-up should not be obtained solely for determination of eligibility for protocol 9846 by these criteria. Once available, final histology must be confirmed to the coordinating site detailing the cancer diagnosis for patients enrolled based on the above criteria
- • Patients with a newly diagnosed primary and/or metastatic solid tumor or hematologic malignancy for which they have not yet received treatment
- * Patients with a solid tumor or hematologic malignancy that is recurrent, newly metastasized, or progressing while on treatment indicated by:
- • Radiographic evidence of tumor growth, re-growth, and/or new metastases, OR
- • Documentation by the treating physician of clinical disease progression, OR
- • CBC w/differential and/or flow cytometry for hematologic malignancies
- • Patients currently undergoing treatment (adjuvant, neoadjuvant, etc.)
- • Specimen collection should occur as distant in time from the most recent drug administration as possible (e.g., after completion of a treatment cycle and immediately prior to initiation of the next cycle)
- • Specimens should not be collected from patients between doses within a single treatment cycle
- • Confirmation of viable residual malignancy and/or \< 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the National Cancer Institute (NCI) coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report
- • Patients with ongoing partial response (PR) or stable disease (SD) are eligible
- • Confirmation of viable malignancy and/or \< 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the NCI coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report
- • Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol
- • For pediatric patients, ability and willingness to assent to participation, using an explanation that is understandable/age appropriate, as well as receiving parental permission. Signature requirements for pediatric patients can be adjusted based on local guidelines
- Exclusion Criteria:
- • Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)
- • Patients with invasive fungal infections
- • Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection
- • Actively febrile patients with uncertain etiology of febrile episode
- • All antibiotics prescribed for the treatment of a bacterial infection should be completed at least 1 week (7 days) prior to collection
- • Patients with a hematologic malignancy who are treated with an antibiotic, anti-fungal, and/or anti-viral medication for an active infection who then remain on the treatment for prophylaxis following resolution of the infection as assessed by the treating physician are not excluded
- • No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
- • Patients receiving antibiotics, antifungals, and/or antivirals for prophylaxis are permissible
- • Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible
- • Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus \[HBV\]-deoxyribonucleic acid \[DNA\] and/or positive hepatitis B surface antigen \[HbsAg\], quantifiable hepatitis C virus \[HCV\]-ribonucleic acid \[RNA\]) or known history of HCV, HBV, or HIV; testing for HBV, HCV, HIV or other infections for eligibility will be performed only if clinically indicated
- • Patients with hepatitis A as indicated by anti-hepatitis A virus (HAV) IgM reactivity
- • Patients that are anti-HAV IgG reactive only are eligible
- • Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR)
About National Cancer Institute Lao
The National Cancer Institute Lao (NCIL) is a leading research organization dedicated to advancing cancer prevention, treatment, and care within Lao PDR. As a sponsor of clinical trials, NCIL focuses on conducting innovative research that addresses the unique cancer-related challenges faced by the population. With a commitment to collaboration, the institute works closely with international partners, healthcare providers, and researchers to enhance cancer research capabilities and improve patient outcomes. Through its rigorous clinical trials, NCIL aims to contribute valuable insights to the global cancer research community and promote evidence-based practices in oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Durham, North Carolina, United States
Saint Louis, Missouri, United States
Peoria, Illinois, United States
Boston, Massachusetts, United States
Wichita, Kansas, United States
Duarte, California, United States
La Crosse, Wisconsin, United States
Chanute, Kansas, United States
Dodge City, Kansas, United States
Newton, Kansas, United States
Wellington, Kansas, United States
Winfield, Kansas, United States
Kalamazoo, Michigan, United States
Traverse City, Michigan, United States
Houston, Texas, United States
Mount Vernon, Illinois, United States
Salina, Kansas, United States
Wichita, Kansas, United States
Ann Arbor, Michigan, United States
Effingham, Illinois, United States
Fort Scott, Kansas, United States
Independence, Kansas, United States
Lawrence, Kansas, United States
Saint Joseph, Missouri, United States
Springfield, Illinois, United States
Springfield, Illinois, United States
Boston, Massachusetts, United States
Birmingham, Alabama, United States
Los Angeles, California, United States
Aurora, Colorado, United States
Baltimore, Maryland, United States
Saint Louis, Missouri, United States
Bronx, New York, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Seattle, Washington, United States
Newark, Delaware, United States
Bronx, New York, United States
Auburn, Washington, United States
Puyallup, Washington, United States
Cape Girardeau, Missouri, United States
Saint Louis, Missouri, United States
Memphis, Tennessee, United States
Augusta, Georgia, United States
Rochester, Minnesota, United States
Saint Louis, Missouri, United States
Bronx, New York, United States
Marshfield, Wisconsin, United States
Decatur, Illinois, United States
Bloomington, Illinois, United States
Ottawa, Illinois, United States
Peoria, Illinois, United States
Peoria, Illinois, United States
El Dorado, Kansas, United States
Kingman, Kansas, United States
Parsons, Kansas, United States
Pratt, Kansas, United States
Wichita, Kansas, United States
Wichita, Kansas, United States
Galesburg, Illinois, United States
Reed City, Michigan, United States
Cape Girardeau, Missouri, United States
Peru, Illinois, United States
Kalamazoo, Michigan, United States
Galesburg, Illinois, United States
Pekin, Illinois, United States
Wichita, Kansas, United States
Battle Creek, Michigan, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Saint Joseph, Michigan, United States
Joplin, Missouri, United States
Springfield, Missouri, United States
Springfield, Missouri, United States
Eau Claire, Wisconsin, United States
Minocqua, Wisconsin, United States
Rice Lake, Wisconsin, United States
Stevens Point, Wisconsin, United States
Wausau, Wisconsin, United States
Weston, Wisconsin, United States
Chicago, Illinois, United States
Livonia, Michigan, United States
Saint Joseph, Michigan, United States
Chippewa Falls, Wisconsin, United States
Canton, Illinois, United States
Carthage, Illinois, United States
Eureka, Illinois, United States
Kewanee, Illinois, United States
Macomb, Illinois, United States
Peru, Illinois, United States
Princeton, Illinois, United States
Springfield, Illinois, United States
Niles, Michigan, United States
Joplin, Missouri, United States
Fort Smith, Arkansas, United States
Bloomington, Illinois, United States
Pekin, Illinois, United States
Liberal, Kansas, United States
Bolivar, Missouri, United States
Branson, Missouri, United States
Saint Louis, Missouri, United States
Saint Louis, Missouri, United States
Peoria, Illinois, United States
Bloomington, Illinois, United States
Arroyo Grande, California, United States
Jefferson City, Missouri, United States
Oklahoma City, Oklahoma, United States
Rolla, Missouri, United States
Rolla, Missouri, United States
Springfield, Illinois, United States
Las Vegas, Nevada, United States
Newark, Delaware, United States
Newark, Delaware, United States
Newark, Delaware, United States
Wilmington, Delaware, United States
Manhattan, Kansas, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Carbondale, Illinois, United States
Centralia, Illinois, United States
Decatur, Illinois, United States
O'fallon, Illinois, United States
Ottawa, Illinois, United States
Bonne Terre, Missouri, United States
Sainte Genevieve, Missouri, United States
Sullivan, Missouri, United States
Sunset Hills, Missouri, United States
Oxford, Mississippi, United States
Gig Harbor, Washington, United States
Bainbridge Island, Washington, United States
Federal Way, Washington, United States
Lynnwood, Washington, United States
New Haven, Connecticut, United States
Springfield, Illinois, United States
Aurora, Colorado, United States
Pekin, Illinois, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Ann Arbor, Michigan, United States
Stevens Point, Wisconsin, United States
Minocqua, Wisconsin, United States
Sunset Hills, Missouri, United States
Niles, Michigan, United States
Reed City, Michigan, United States
Saint Joseph, Michigan, United States
Grand Rapids, Michigan, United States
Saint Joseph, Michigan, United States
Jefferson City, Missouri, United States
Kalamazoo, Michigan, United States
Mount Vernon, Illinois, United States
Patients applied
Trial Officials
James H Doroshow
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials